Recursion Pharma 新闻与活动
在场
是其中之一......
Recursion Pharma 是一家在股票代码 RXRX (US) 下上市的公司。
Recursion Pharma 在 3 个国家有直接业务。
他们在：
涉及Recursion Pharma的并购和融资。
- Recursion Pharma and Exscientia have merged (公布2024十一月27号)..
- Recursion Pharma 刚刚宣布为 50 筹款数百万美元。 (公布2023七月17号).
- Recursion Pharma has announced the acquisition of Cyclica (公布2023五月12号).
高管
查看带有其 68 名主要高管的组织结构图
Recursion Pharma 搜索最多的简介
- Chris Gibson, Chief Executive Officer and Director
- Zavain Dar, Board Member
- Blake Borgeson, Director
高管在Recursion Pharma变化
- Elaine Sun已作为Director加入公司 (新闻发布的2025三月20号).
- Namandjé Bumpus已作为Director加入公司 (新闻发布的2025三月20号).
- Ben Taylor已作为Chief Financial Officer and President, UK加入公司 (新闻发布的2024十一月27号).
创建提醒
跟踪 Recursion Pharma 的高管变动
药店
Recursion Pharma 拥有 1,834 家竞争者，其中包括 Pfizer (美国(美洲))、Eli Lilly (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Clario 已收购 NRx Pharmaceuticals (公布2025三月18号).
- Knight Therapeutics has announced the acquisition of Paladin Labs (公布2025三月12号).
- Jazz Pharmaceuticals 已收购 Chimerix (公布2025三月6号).
药店 行业的其他推荐联系人
消息
Recursion Pharma 的最新新闻稿
- Recursion and Google Cloud Announce Expansion of Partnership to Support Drug Discovery with Cloud and Exploration of Generative AI Technologies
- Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma | Recursion Pharmaceuticals, Inc.
- Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability | Recursion Pharmaceuticals, Inc.
- Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities | Recursion Pharmaceuticals, Inc.
- Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer | Recursion Pharmaceuticals, Inc.
- Recursion Announces Plans to Open New Office in London | Recursion Pharmaceuticals, Inc.
- Recursion to Host Public L(earnings) Call on February 27 | Recursion Pharmaceuticals, Inc.
- Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology | Recursion Pharmaceuticals, Inc.
- Press Releases | Recursion Pharmaceuticals, Inc.
- Press Releases | Recursion Pharmaceuticals, Inc.
- View more press releases Close
